Adam Feuerstein

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.

This is STAT's ASCO in 30 Seconds newsletter You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting.

Here is some of what you may have missed from the world's largest cancer research meeting.

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches?

Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.

A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.

Proving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug